ACT Brief: Product Development Assumptions, Portfolio-Level Recruitment Infrastructure, and Risk-Based Quality Integration

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part two of her interview, Elizabeth Walsh, founder of Walsh Clinical Advisory and co-author of The Clinical Execution Blueprint, made the case that assumptions accumulated at the moment of a product development decision govern everything that follows. Deferring that critical work doesn't save time; it only makes it more expensive to fix downstream.
• In a new Q&A, Gaynor Anders, chief delivery officer at Trialbee, discussed how the FDA's single pivotal trial shift requires portfolio-level recruitment with shared budgets and cross-functional collaboration replacing siloed study teams. Success demands technology integration between patient recruitment platforms and CTMS systems enabling end-to-end analytics, alongside true partnership between sponsors, CROs, and recruitment providers to move patients through the complete funnel.
• In a Q&A on Pharmaceutical Technology, Jeffrey Mocny of Abzena and Anna McMahon of Cellares discussed how risk-based quality frameworks must be embedded into process design from the outset rather than treated as operational overlays. Implementing these frameworks requires cross-functional quality review boards, a risk-aware culture, and rigorous data integrity to establish clear linkages between manufacturing unit operations and clinical performance.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.